Volume 28 Number 5
31 May 2016

Home > Publications > Current Neuro-Oncology > Volume 18, Year 2016 > Number 5, 31 May

Cihan YB.
Role of Re-irradiation in Salvage Treatment of Glioblastoma Multiforme.
Asian Pac J Cancer Prev. 2016 May, 2016;17(5):2729-30
. PMID: 27268660. Letter to the Editor. ˍ

Koschmann C, Bloom K, Upadhyaya S, Geyer JR, Leary SE.
Survival After Relapse of Medulloblastoma.
J Pediatr Hematol Oncol. 2016 May;38(4):269-73
. doi: 10.1097/MPH.0000000000000547. PMID: 26907655. Observational study; ˍ

Lafay-Cousin L, Smith A, Chi SN, Wells E, Madden J, Margol A, Ramaswamy V, Finlay J, Taylor MD, Dhall G, Strother D, Kieran MW, Foreman NK, Packer RJ, Bouffet E.
Clinical, Pathological, and Molecular Characterization of Infant Medulloblastomas Treated with Sequential High-Dose Chemotherapy.
Pediatr Blood Cancer. 2016 May 4. 2016;63(9):1527-34. doi: 10.1002/pbc.26042. PMID: 27145464. Observational study. ˍ
Erratum in: Pediatr Blood Cancer. 2017 Jan 4. 2017;64(4):e26435. doi: 10.1002/pbc.26435. PMID: 28221730 Correction. ˍ

Pajtler KW, Tippelt S, Siegler N, Reichling S, Zimmermann M, Mikasch R, Bode U, Gnekow A, Pietsch T, Benesch M, Rutkowski S, Fleischhack G.
Intraventricular etoposide safety and toxicity profile in children and young adults with refractory or recurrent malignant brain tumors.
J Neurooncol. 2016 May 4, 2016;128(3):463-71
. doi: 10.1007/s11060-016-2133-x. PMID: 27147083. Interventional study. ˍ

Schneider H, Weller M.
Boswellic acid activity against glioblastoma stem-like cells.
Oncol Lett. 2016 May 4, 2016;11(6):4187-4192
. doi: 10.3892/ol.2016.4516. PMID: 27313764 Laboratory investigation. ˍ

Ene CI, Nerva JD, Morton RP, Barkley AS, Barber JK, Ko AL, Silbergeld DL.
Safety and efficacy of carmustine (BCNU) wafers for metastatic brain tumors.
Surg Neurol Int. 2016 May 6, 2016;7(Suppl 11):S295-9
. doi: 10.4103/2152-7806.181987. PMID: 27217968. Observational study. ˍ

Carter T, Shaw H, Cohn-Brown D, Chester K, Mulholland P.
Ipilimumab and Bevacizumab in Glioblastoma.
Clin Oncol (R Coll Radiol). 2016 May 8, 2016 Oct;28(10):622-626
. doi: 10.1016/j.clon.2016.04.042. PMID: 27169593. Observational study. ˍ

Lee J, Cho J, Chang JH, Suh CO.
Re-Irradiation for Recurrent Gliomas: Treatment Outcomes and Prognostic Factors.
Yonsei Med J. 2016 May 10, 2016;57(4):824-30
. doi: 10.3349/ymj.2016.57.4.824. PMID: 27189273. Observational study. ˍ

Samal F, Stanek L, Filip M, Haninec P, Vícha A, Musil Z, Tesarova P, Petruzelka L, Springer D, Kralickova M, Kohoutova M, Zima T.
Complete diagnostics and clinical approach for a female patient with unusual glioblastoma: A case study.
Mol Clin Oncol. 2016 May 10, 2016;5(1):161-164
. doi: 10.3892/mco.2016.891. PMID: 27330791. Case report. ˍ

Lombardi G, Bellu L, Pambuku A, Della Puppa A, Fiduccia P, Farina M, D'Avella D, Zagonel V.
Clinical outcome of an alternative fotemustine schedule in elderly patients with recurrent glioblastoma: a mono-institutional retrospective study.
J Neurooncol. 2016 May 11, 2016;128(3):481-6
. doi: 10.1007/s11060-016-2136-7. PMID: 27165580. Observational study. ˍ

Cha Y, Kim YJ, Lee SH, Kim TM, Choi SH, Kim DW, Park CK, Kim IH, Kim JH, Kim E, Choi B, Kim CY, Kim IA, Heo DS.
Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma.
Cancer Res Treat. 2016 May 18, 2017;49(1):129-140
. doi: 10.4143/crt.2015.466. PMID: 27188199. Observational study. ˍ

Liu HL, Hsu PH, Lin CY, Huang CW, Chai WY, Chu PC, Huang CY, Chen PY, Yang LY, Kuo JS, Wei KC.
Focused Ultrasound Enhances Central Nervous System Delivery of Bevacizumab for Malignant Glioma Treatment.
Radiology. 2016 May 18, 2016;281(1):99-108
. doi: 10.1148/radiol.2016152444. PMID: 27192459. Laboratory investigation. ˍ

Schaub C, Tichy J, Schäfer N, Franz K, Mack F, Mittelbronn M, Kebir S, Thiepold AL, Waha A, Filmann N, Banat M, Fimmers R, Steinbach JP, Herrlinger U, Rieger J, Glas M, Bähr O.
Prognostic factors in recurrent glioblastoma patients treated with bevacizumab.
J Neurooncol. 2016 May 18, 2016;129(1):93-100
. doi: 10.1007/s11060-016-2144-7. PMID: 27193554. Observational study. ˍ

Cheng W, Ren X, Zhang C, Cai J, Liu Y, Han S, Wu A.
Bioinformatic profiling identifies an immune-related risk signature for glioblastoma.
Neurology. 2016 May 25, 2016;86(24):2226-34. doi: 10.1212/WNL.0000000000002770. PMID: 27225222. Laboratory investigation. _

Brown N, McBain C, Nash S, Hopkins K, Sanghera P, Saran F, Phillips M, Dungey F, Clifton-Hadley L, Wanek K, Krell D, Jeffries S, Khan I, Smith P, Mulholland P.
Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma.
PLoS One. 2016 May 27;11(5):e0156369
. doi: 10.1371/journal.pone.0156369. PMID: 27232884. Interventional study. ˍ